Series C Round

Antheia Bio is focused on delivering commercial-scale shipments of thebaine, a key starting material for Narcan. The company leverages synthetic biology to produce biosynthetic Key Starting Materials (KSMs) and Active Pharmaceutical Ingredients (APIs) for essential medicines. This funding will accelerate the development of their biomanufacturing platform, which utilizes engineered yeast and advanced fermentation technology to address global drug shortages and enhance the availability of critical medications. Antheia aims to revolutionize the pharmaceutical supply chain by providing a sustainable and reliable source of essential drugs.